At Innova Medical Group, we believe that innovation enables the development of ever faster screening methods and thus contributes to everyone living longer in better health.

Innova Medical Group is among the first in the medical technology field to offer a rapid antigen test that meets the highest standards of quality and accuracy for COVID-19 screening.  Because Innova’s high standards ensures reproducible performance in large-scale production, in less than two years, more than two and a half billion units will have been distributed worldwide.

Innova Medical Group supports and partners with academic and private institutions in the development of technological and industrial advancements. As business and technological maturity are reached, these innovations are commercialized and scaled by Innova Medical Group with the aim of making them accessible and available to everyone, boosting their availability via our worldwide distribution network.

Le modèle d’innovation d’Innova Medical Group consiste donc à être le catalyseur d’un écosystème d’innovations et l’accélérateur de leur mise à disposition via notre réseau mondial de distribution.

Several products, not yet available in France, are already offered in several countries around the world:

  • The combined SARS-CoV-2 and Influenza A and/or B self-test allows for the detection of SARS-CoV-2 and Influenza A and/or B antigens in less than 15 minutes through a simple, non-invasive and painless nasal swab.

  • The SARS-CoV-2 Saliva Self-Test, which is over 99% accurate, provides qualitative detection of SARS-CoV-2 antigen in a simple saliva sample.

  • The SARS-CoV-2 serological self-test qualitatively detects the presence of IgG anti-S and anti-RBD antibodies in a blood capillary sample.

Innova Medical Group, an innovative MedTech on a global scale

The Innova Medical Group is a specialist in innovative solutions for the rapid screening and diagnosis of infectious diseases, chronic diseases, and everyday health and wellness.

A pioneer in the fight against Covid-19 with more than 2.5 billion units sold in 2 years, Innova Medical Group has expanded its offerings to include a wide range of rapid tests for SARS-CoV-2, influenza and strep throat, as well as a complete line of self-tests for everyday health and wellness.

In France, an assembly and packaging site for its tests, with a production capacity of up to 5 million tests per month, was inaugurated in October 2021 in Pithiviers, in the Loiret region, in the heart of Europe’s leading pharmaceutical cluster, Polepharma.

By the end of 2022, Innova Medical Group will continue to expand and proactively work to bring other innovative screening and rapid diagnostic solutions to market.



You can contact us via the form or directly by email: contact@innovamedgroup.fr


    First Name